2026 ASH®
Annual Meeting & Exposition December 12-15, 2026 ▪ New Orleans, Louisiana

Paper Details

Abstracts, authors, affiliations, and disclosures.

Sunday, December 13, 2026
12:00 p.m. - 01:30 p.m.
MCCNO - New Orleans Theatre B
Access, Representation, Population Health, Treatment Considerations, Combination Therapy, Biological Therapies, Bispecific Antibody Therapy, Checkpoint Inhibitor, Immunotherapy, Non-Biological Therapies, Chemotherapy, Diseases, Lymphoid Malignancies, Lymphomas, Non-Hodgkin Lymphoma, B Cell Lymphoma, Aggressive Lymphoma, Research, Clinical Research, Clinical Trials, Study Population, Human, Adult, Elderly
PAPER

620 3-year follow-up of glofitamab combined with chemotherapy for the initial treatment of younger patients with high-risk LBCL confirms ongoing favorable safety profile and durable disease control: Final analysis of the coalition trial

Adrian Minson, MBBS, PhD, Emma Verner, MBBS2, Pratyush Giri Sr, MBBS3, Jason Butler, MBBS4, Wojciech Janowski, MBChB FRACP FRCPA5, Chan Cheah, MBBS, DMSc6, Sumita Ratnasingam, MD, FRACP, FRCPA7, Shu Min Wong, MBBS8, Matthew Ku, MBBS,PhD9, Mark Hertzberg, MD, PhD10, Kirsten Herbert, MBBS, PhD11, Nada Hamad, MBBS, MSc, BSc12, Costas K Yannakou13, Fiona Swain, MBBS14, Paul J Neeson, PhD15, Thiago Maass Steiner, PhD16, Javad Saghebi17, Piers Blombery, PhD18, Sally Hunter Jr, PhD19, Molly Robertson, RN, MAdvNursPrac20, LeiShong Lau21, Rory Bennett, MBChB22, Sean Harrop, MBBS23, Jing Xie, PhD24, John F. Seymour, MBBS, PhD25, Michael Dickinson, MBBS (Hons), DMedSci FRACP, FRCPA26
1 Peter MacCallum Cancer Centre & Royal Melbourne Hospital, Melbourne, Victoria, Australia
2 Concord Repatriation Hospital, Sydney, Australia
3 Royal Adelaide Hospital, Adelaide, Australia
4 Royal Brisbane & Womens Hospital, Brisbane, Australia
5 Calvary Mater, Newcastle, Australia
6 Sir Charles Gairdner Hospital, Perth, Australia
7 Barwon Health, Geelong, Australia
8 Alfred Health, Melbourne, Australia
9 St Vincent's Hospital, Melbourne, Australia
10 Prince of Wales Hospital, Sydney, Australia
11 Cabrini Health, Melbourne, Australia
12 St Vincent's Hospital, Sydney, Australia
13 Epworth HealthCare, Melbourne, Australia
14 Princess Alexandra Hospital, Brisbane, Australia
15 Peter MacCallum Cancer Centre & Royal Melbourne Hospital, Melbourne, Victoria, Australia
16 Peter MacCallum Cancer Centre & Royal Melbourne Hospital, Melbourne, Victoria, Australia
17 Peter MacCallum Cancer Centre & Royal Melbourne Hospital, Melbourne, Victoria, Australia
18 Peter MacCallum Cancer Centre & Royal Melbourne Hospital, Melbourne, Victoria, Australia
19 Peter MacCallum Cancer Centre & Royal Melbourne Hospital, Melbourne, Victoria, Australia
20 Peter MacCallum Cancer Centre & Royal Melbourne Hospital, Melbourne, Victoria, Australia
21 Peter MacCallum Cancer Centre & Royal Melbourne Hospital, Melbourne, Victoria, Australia
22 Peter MacCallum Cancer Centre & Royal Melbourne Hospital, Melbourne, Victoria, Australia
23 Peter MacCallum Cancer Centre & Royal Melbourne Hospital, Melbourne, Victoria, Australia
24 Peter MacCallum Cancer Centre & Royal Melbourne Hospital, Melbourne, Victoria, Australia
25 Peter MacCallum Cancer Centre & Royal Melbourne Hospital, Melbourne, Victoria, Australia
26 Peter MacCallum Cancer Centre & Royal Melbourne Hospital, Melbourne, Victoria, Australia

Introduction: The CD20-CD3 bispecific antibody glofitamab (glofit) has efficacy in LBCL as monotherapy (Dickinson, NEJM 2022), and when combined with chemotherapy improves survival in R/R disease (Abramson, Lancet 2024). Patients with newly diagnosed high-risk (HR) LBCL have poor outcomes with standard or intensified chemotherapy. Initial results of glofit with R-CHOP or Pola-R-CHP demonstrated high rates of complete response (CR) in a HR, high tumor burden population (COALITION, Minson, JCO 2025). Here, we present the final analysis of COALITION, with median follow up (f/up) of 39.2 months (mo).

Methods: Patients (pts) aged 18 to 65 y with newly diagnosed HR-LBCL were enrolled prior to or after one cycle of R-CHOP and randomized to receive either Glofit-R-CHOP (Arm A) or Glofit-Pola-R-CHP (Arm B). All pts were treated with 1 cycle of R-CHOP and 5 combination induction cycles (with glofit step-up dosing in cycle 2), followed by 2 cycles of glofit monotherapy. HR-LBCL was defined as IPI ≥3, NCCN-IPI ≥4, or proven HGBL with MYC and BCL2 and/or BCL6 rearrangements (HGBL-DH). The primary endpoint was safety and tolerability; secondary endpoints included OS and PFS. Responses were investigator-determined using Lugano 2014 criteria. Measurable residual disease (MRD) in cfDNA was assessed using the KAPA HyperCap DS NHL panel (Roche Diagnostics). Dark zone signature (DZsig) was determined from bulk RNASeq data.

Results: Eighty pts were treated, 40 in each arm. Pt characteristics were: median age 58y (range 24-65), 64% male, 97% stage III-IV, 45% non-GCB, and median TMTV 842 (range 3-4150) cm3. HR features were IPI ≥3 in 84%, NCCN-IPI ≥4 in 85% and HGBL-DH in 11%. In pts with available samples, TP53 mutations were identified in 29% (16/56) and DZsig+ in 17% (11/66). Therapy was well tolerated with no new safety signals. Treatment delivery and intensity was maintained; 79/80 pts received all planned cycles of therapy and the median relative dose intensity was ≥94% for all agents. Treatment emergent AEs were reported in 99% of pts; the most common of any grade were peripheral neuropathy (44%), neutropenia (34%), nausea (29%) and CRS. Rates and grades of CRS were unchanged from the original report, occurring in 21% (G1 19%, G2 2%). Infections occurring after end of treatment (EOT) were uncommon; 7 pts (9%) had 9 infection events (respiratory [n=8], bladder [n=1]), all grade 1-2, at median of 365 (range 257-849) days. Hypogammaglobulinemia with IgG <7 g/L was seen in 60% of pts, with 72% subsequently normalizing. There were 6 deaths, 4 due to lymphoma (1 new from previous report), 1 from AML and 1 from viral pneumonia. The best OR and CR rates were 100% and 98%, respectively. With a median 39.2 mo f/up, the 24- and 36-mo PFS and OS were 89% and 85%, and 92% and 92%, respectively. PFS and OS were similar between the arms. There was a total of 13 PFS events; 11 PD events (8 high grade and 3 indolent) and 2 deaths in CR. Of the 11 with PD, the median time from EOT to PD was 12 mo. Of the 3 pts with biopsy-proven indolent relapse, all progressed late (at 24, 25 and 31 mo from EOT); only one had prior history of indolent lymphoma. Three pts had primary progressive disease before EOT, and all died from lymphoma despite salvage treatments (at 6, 10, and 17 mo from PD); in comparison, 7 of 8 pts with later relapse remained alive with short f/up from PD (median 2 (range 0-21) mo). Of 6 pts with available samples at PD, all remained CD20 positive by IHC. Sub-groups with known TP53 mutation and DZsig+ had 2-yr PFS 94% and 91%, respectively. In a sensitivity analysis excluding pts with biopsy-proven indolent relapse, the 24- and 36-mo PFS from LBCL were 89% and 88%, respectively. Of 61 pts evaluable for MRD by cfDNA, 91% were MRD negative at EOT. Of the 5 pts with MRD positivity at EOT, 2 had PD at that time, while the remaining 3 in CR have not progressed with median f/up of 28 mo (range 2-36) beyond EOT.

Conclusions: With a median of >3 years follow up, the combination of glofit with R-CHOP or Pola-RCHP in a younger, HR, high tumor-burden population resulted in 98% CRR and high rates of durable MRD-negative remission; the 24-mo PFS and OS were 89% and 92%, respectively. Few pts had additional low-grade infection events without new safety signals. These results support the potential role for glofit combined with chemotherapy in improving outcomes for HR-LBCL, currently being evaluated in the ongoing randomized SKYGLO trial (NCT06047080).

Adrian Minson, MBBS, PhD: AbbVie - Honoraria; Gilead - Honoraria; Kite - Honoraria; F Hoffman La Roche - Honoraria; Lilly - Research Funding; F Hoffman La Roche - Research Funding; AbbVie - Research Funding; Loxo - Research Funding